Puerto Rico Cannabis Industry by the Numbers (2026)

The Short Version

Puerto Rico is a medical-only jurisdiction. Licensed cannabis requires a valid medical patient registration with the JRCM. The program has been running for a decade, and as of 2026 it is a mature medical market by most measures, with dispensary density comparable to mainstream US medical states, a patient population in the tens of thousands, and an annual sales figure that puts it in the same rough bracket as Rhode Island or Vermont.

This piece is a data snapshot. Where the numbers are firm (licensed operator counts published by the Junta Reglamentadora de Cannabis Medicinal), they are cited as firm. Where they are estimates (market-size figures, patient-visit counts, price points), they are flagged as estimates. The intent is to give adults 21+ with a valid patient registration, plus operators and industry observers, a defensible read on what the Puerto Rico market looks like in 2026.

Dispensary Count

The operational figure: around 100 licensed dispensaries are serving patients across Puerto Rico as of early 2026. The JRCM publishes the licensed-operator list through its official channels; the count has hovered in the 90-120 range for the last several years, with some churn at the margins as operators enter and exit.

Distribution skews heavily toward the San Juan metro. A rough geographic breakdown of dispensary locations:

• San Juan metro (Old San Juan, Condado, Santurce, Miramar, Isla Verde, Carolina, Bayamón, Guaynabo): roughly 40-50 shops, the clear gravity center
• East coast (Fajardo, Luquillo, Rio Grande, Humacao): 8-12 shops serving the El Yunque + off-island corridor
• West coast (Rincón, Aguadilla, Isabela, Mayagüez): 10-15 shops across the surf-town and university belt
• South coast (Ponce, Cabo Rojo, Guanica): 8-10 shops
• Central mountains (Caguas, Cayey, Adjuntas): 6-10 shops
• Off-islands (Vieques, Culebra): near-zero licensed retail. Patients typically shop on the main island before ferry crossings.

This distribution matters for visitor planning: a tourist anchored in San Juan has dozens of options within a 20-minute cab ride. A tourist staying in a west-coast surf town or a south-coast beach town has fewer, and the shops that do operate in smaller markets tend to have shorter hours.

Dispensary Density vs US States

Per-capita density is a reasonable comparison metric. Puerto Rico has a population of roughly 3.2 million. At 100 licensed dispensaries, that's one shop per ~32,000 residents.

For comparison (rough figures, all approximate):

• Oklahoma: one shop per ~1,500 residents (the highest density in the US, an outlier)
• Montana: one shop per ~4,000 residents
• Colorado: one shop per ~6,000 residents
• Oregon: one shop per ~6,500 residents
• Maine: one shop per ~3,500 residents
• Massachusetts: one shop per ~15,000 residents
• Florida: one shop per ~25,000 residents (medical-only, like PR)
• New York: one shop per ~45,000 residents (still scaling, as of 2026)

Puerto Rico sits in the same bracket as Florida. Both are medical-only programs, both are at roughly one shop per 25,000-35,000 residents. That's a mature medical-market density, well above a pre-launch or early-launch state and below the high-churn adult-use markets.

Patient Enrollment

The population of active registered patients in the Puerto Rico program is estimated at 50,000+ as of 2026. This is an estimate; the JRCM has periodically published patient-count figures, and the active population has been in the 40,000-60,000 range across the last several years with a gradual upward trend.

Key splits to understand:

• Resident long-term patients make up the large majority of the active-registration base. These are PR residents with qualifying conditions who renew annually.
• Visiting tourist patients (temporary registrations) add to the total but are a small minority by headcount, though they contribute disproportionately to revenue per transaction.
• Minor patients are a small fraction, operating under stricter oversight. This site's editorial posture treats the program as open to adults 21+; minor-patient mechanics are outside the scope of a tourist guide.

Patient growth peaked during the 2018-2023 launch-and-expansion window, when the program went from a few thousand pilot patients to a five-digit active base. Growth has flattened somewhat since 2023 as the initial addressable population has normalized, with net additions now running closer to a steady-state replacement cadence.

Market Size

Annual legal cannabis sales in Puerto Rico are estimated at roughly $150 million in 2026. This is an estimate; industry analyst reports in this range have been published, and the figure aligns with the observable dispensary count, patient base, and per-transaction norms.

The comparison set:

• Rhode Island legal cannabis sales (medical + nascent adult-use): ~$100-150M annually
• Vermont legal cannabis sales (medical + adult-use): ~$150-200M annually
• New Mexico (medical + adult-use): ~$500M+ annually
• Florida (medical-only, comparable framing to PR): ~$2B annually (population ~7x PR)

On a per-capita basis, PR's roughly $47 per resident per year puts the market below mature adult-use states (Colorado at ~$400 per resident, Oregon at ~$300) and below Florida (~$280 per resident). That is consistent with a medical-only program serving a subset of the population rather than a broad adult-use market.

The Growth Curve, 2018-2023

The Puerto Rico program had two distinct growth phases:

Phase 1 — 2015 to 2018: the pilot years

The 2015 executive order established the program; the first dispensaries opened in 2017. Through 2018, the market was small, with a handful of operators, a few thousand patients, and significant regulatory uncertainty as the JRCM built out its operational framework.

Phase 2 — 2018 to 2023: the expansion years

This was the growth window. Dispensary counts tripled. Patient registrations climbed through the five-digit threshold. The tourist-registration path for visitors became a functioning operational reality by 2019-2020. Hurricane-season disruptions (Maria in 2017, subsequent storms) did not derail the growth curve materially. The COVID-19 era accelerated telehealth-based patient onboarding, including for visitors.

Phase 3 — 2023 to 2026: maturation

Growth has flattened. Dispensary counts have plateaued in the 90-120 range. Patient growth is running closer to replacement. Sales figures are stable year-over-year. The industry has transitioned from "scaling" to "operating."

What the Data Doesn't Capture

Some load-bearing realities that the numbers understate or miss entirely:

• Cash-heavy operations. Federal banking restrictions mean most PR dispensaries are cash-preferred. Reported sales may modestly understate the full market given the friction in electronic-payment reconciliation.
• The illicit market. Puerto Rico, like every jurisdiction with a legal medical program, has a persistent illicit market that predates the legal one. Rough analyst estimates put the illicit market at comparable scale to the legal one, though estimation here is difficult.
• Tourist patient revenue concentration. Visiting patients are small by headcount but contribute disproportionately per visit. Typical visitor transactions run larger than resident-patient maintenance buys. For dispensaries in tourist-heavy districts (Condado, Old San Juan, Rincón), visitors may represent 15-30% of revenue despite being a single-digit percentage of the patient base.
• Product-mix shifts. Flower remains the dominant category by unit volume. Edibles, vapes, and concentrates have gained share over the last five years. Topicals and tinctures are consistently small but steady.

Regulatory Framework Snapshot

The JRCM (Junta Reglamentadora de Cannabis Medicinal) is the program regulator and handles:

• Cultivator licensing
• Processor and manufacturer licensing
• Dispensary licensing
• Patient registration (resident and temporary/visitor)
• Physician certification oversight
• Product testing requirements

Key compliance realities, as of 2026:

• No adult-use market. All sales are patient-registered.
• No interstate commerce. Federal law prohibits transporting cannabis across state or territorial lines, including on flights back to the mainland.
• No on-site consumption. Dispensaries are retail-only; there is no licensed lounge category at the scale of states like Nevada or New Jersey.
• Testing standards. JRCM-licensed product is laboratory-tested, and test results are available at the point of sale.

What This Means for a Visiting Patient

For an adult 21+ visitor with a valid patient registration in hand, the data translates roughly as follows:

• Selection is wide. Roughly 100 licensed shops across the island. A San Juan-based trip puts dozens of options within a cab ride.
• Pricing is reasonable. Per-gram and per-package pricing in 2026 runs comparable to mainstream US medical markets. Some importers price above mainland norms; most local operators price at or slightly below.
• Product quality is solid. The regulated market has matured to the point where the typical licensed shop carries lab-tested flower, pre-rolls, edibles, vapes, tinctures, and topicals in a familiar product-category set.
• The paperwork is the gate. The program's size and maturity do not change the core operational reality: the temporary patient registration is what unlocks all of the above. Without it, none of these 100 shops can sell to a visitor.

Compliance

• Puerto Rico is a medical-only jurisdiction. Licensed cannabis requires a valid medical patient registration with the JRCM.
• 21+ with a valid patient registration.
• No on-site consumption at any licensed dispensary.
• No consumption in public spaces or on federally-managed land.
• Federal law prohibits transporting cannabis across state or territorial lines, including on flights back to the mainland.
• Start low, go slow for any product category, especially for first-time patients in a new market.

Where to Go Next

• The tourist patient registration guide
• How Puerto Rico's program compares to US states
• Medical vs street cannabis, and why legal matters

This is editorial, not legal advice. Figures cited as estimates are clearly marked.